Influence of treatment on the clinical course of pemphigus vulgaris
Pemphigus vulgaris (PV) is a potentially fatal autoimmune blistering disease. Our purpose was to summarize reported results of treatment for PV and suggest a basis for future studies. This retrospective review applies objective criteria to 77 studies published during the last half century. It inculu...
Gespeichert in:
| Veröffentlicht in: | Journal of the American Academy of Dermatology 1996-04, Vol.34 (4), p.645-652 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 652 |
|---|---|
| container_issue | 4 |
| container_start_page | 645 |
| container_title | Journal of the American Academy of Dermatology |
| container_volume | 34 |
| creator | Carson, Patrick J. Hameed, Ahsan Ahmed, A. Razzaque |
| description | Pemphigus vulgaris (PV) is a potentially fatal autoimmune blistering disease.
Our purpose was to summarize reported results of treatment for PV and suggest a basis for future studies.
This retrospective review applies objective criteria to 77 studies published during the last half century. It inculudes only patients older than 18 years of age with idiopathic PV and excludes patients with drug-induced PV.
Systemic corticosteroids significantly (
p = 0.001) reduced the mortality rate associated with PV compared with no treatment in the presteroid era. Adjuvants used with steroids significantly (
p = 0.001) reduced the mortality rate compared with the steroid era. The mortality rate of Jewish patients is significantly (
p = 0.001) higher than for non-Jewish patients. The outcome of PV is not influenced by the site of the initial lesion.
Although the retrospective nature of this review limits its validity, we conclude prednisone with an adjuvant is the preferred treatment, and methotrexate should be avoided. |
| doi_str_mv | 10.1016/S0190-9622(96)80066-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77962152</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0190962296800661</els_id><sourcerecordid>77962152</sourcerecordid><originalsourceid>FETCH-LOGICAL-c507t-9f267b3e21eeb585390acff3dc19ccc84a593dac5a7b0ec284feea3753a81e933</originalsourceid><addsrcrecordid>eNqFkEtLAzEQgIMotVZ_QmEPInpYTTbNZnMSKT4KBQ_qOaSzkzayj5rsFvz3pg969TJzmG9eHyFjRu8ZZfnDB2WKpirPsluV3xWU5nnKTsiQUSXTXBbylAyPyDm5COGbUqomXA7IoMjjCCGGZDprbNVjA5i0Nuk8mq7GpkvaJulWmEDlGgemSqDtfdgxa6zXK7fsQ7Lpq6XxLlySM2uqgFeHPCJfL8-f07d0_v46mz7NUxBUdqmyWS4XHDOGuBCF4IoasJaXwBQAFBMjFC8NCCMXFCErJhbRcCm4KRgqzkfkZj937dufHkOnaxcAq8o02PZBSxlfZSKLoNiD4NsQPFq99q42_lczqrfy9E6e3pqJQe_kaRb7xocF_aLG8th1sBXr14e6CVGK9aYBF44Yp1wWVEXscY9hlLFx6HUAt1VcOo_Q6bJ1_xzyB7vOi_c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77962152</pqid></control><display><type>article</type><title>Influence of treatment on the clinical course of pemphigus vulgaris</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Carson, Patrick J. ; Hameed, Ahsan ; Ahmed, A. Razzaque</creator><creatorcontrib>Carson, Patrick J. ; Hameed, Ahsan ; Ahmed, A. Razzaque</creatorcontrib><description>Pemphigus vulgaris (PV) is a potentially fatal autoimmune blistering disease.
Our purpose was to summarize reported results of treatment for PV and suggest a basis for future studies.
This retrospective review applies objective criteria to 77 studies published during the last half century. It inculudes only patients older than 18 years of age with idiopathic PV and excludes patients with drug-induced PV.
Systemic corticosteroids significantly (
p = 0.001) reduced the mortality rate associated with PV compared with no treatment in the presteroid era. Adjuvants used with steroids significantly (
p = 0.001) reduced the mortality rate compared with the steroid era. The mortality rate of Jewish patients is significantly (
p = 0.001) higher than for non-Jewish patients. The outcome of PV is not influenced by the site of the initial lesion.
Although the retrospective nature of this review limits its validity, we conclude prednisone with an adjuvant is the preferred treatment, and methotrexate should be avoided.</description><identifier>ISSN: 0190-9622</identifier><identifier>EISSN: 1097-6787</identifier><identifier>DOI: 10.1016/S0190-9622(96)80066-1</identifier><identifier>PMID: 8601655</identifier><identifier>CODEN: JAADDB</identifier><language>eng</language><publisher>New York, NY: Mosby, Inc</publisher><subject>Adjuvants, Pharmaceutic - administration & dosage ; Adjuvants, Pharmaceutic - therapeutic use ; Adult ; Aged ; Anti-Inflammatory Agents - administration & dosage ; Anti-Inflammatory Agents - therapeutic use ; Autoimmune Diseases - drug therapy ; Autoimmune Diseases - physiopathology ; Biological and medical sciences ; Contraindications ; Dermatologic Agents ; Disease Progression ; Female ; Glucocorticoids - administration & dosage ; Glucocorticoids - therapeutic use ; Humans ; Immunosuppressive Agents - administration & dosage ; Immunosuppressive Agents - therapeutic use ; Jews ; Male ; Medical sciences ; Methotrexate ; Middle Aged ; Pemphigus - drug therapy ; Pemphigus - physiopathology ; Pharmacology. Drug treatments ; Prednisone - administration & dosage ; Prednisone - therapeutic use ; Reproducibility of Results ; Retrospective Studies ; Skin, nail, hair, dermoskeleton ; Survival Rate</subject><ispartof>Journal of the American Academy of Dermatology, 1996-04, Vol.34 (4), p.645-652</ispartof><rights>1996 the American Academy of Dermatology, Inc.</rights><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c507t-9f267b3e21eeb585390acff3dc19ccc84a593dac5a7b0ec284feea3753a81e933</citedby><cites>FETCH-LOGICAL-c507t-9f267b3e21eeb585390acff3dc19ccc84a593dac5a7b0ec284feea3753a81e933</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0190962296800661$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3037809$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8601655$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Carson, Patrick J.</creatorcontrib><creatorcontrib>Hameed, Ahsan</creatorcontrib><creatorcontrib>Ahmed, A. Razzaque</creatorcontrib><title>Influence of treatment on the clinical course of pemphigus vulgaris</title><title>Journal of the American Academy of Dermatology</title><addtitle>J Am Acad Dermatol</addtitle><description>Pemphigus vulgaris (PV) is a potentially fatal autoimmune blistering disease.
Our purpose was to summarize reported results of treatment for PV and suggest a basis for future studies.
This retrospective review applies objective criteria to 77 studies published during the last half century. It inculudes only patients older than 18 years of age with idiopathic PV and excludes patients with drug-induced PV.
Systemic corticosteroids significantly (
p = 0.001) reduced the mortality rate associated with PV compared with no treatment in the presteroid era. Adjuvants used with steroids significantly (
p = 0.001) reduced the mortality rate compared with the steroid era. The mortality rate of Jewish patients is significantly (
p = 0.001) higher than for non-Jewish patients. The outcome of PV is not influenced by the site of the initial lesion.
Although the retrospective nature of this review limits its validity, we conclude prednisone with an adjuvant is the preferred treatment, and methotrexate should be avoided.</description><subject>Adjuvants, Pharmaceutic - administration & dosage</subject><subject>Adjuvants, Pharmaceutic - therapeutic use</subject><subject>Adult</subject><subject>Aged</subject><subject>Anti-Inflammatory Agents - administration & dosage</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Autoimmune Diseases - drug therapy</subject><subject>Autoimmune Diseases - physiopathology</subject><subject>Biological and medical sciences</subject><subject>Contraindications</subject><subject>Dermatologic Agents</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Glucocorticoids - administration & dosage</subject><subject>Glucocorticoids - therapeutic use</subject><subject>Humans</subject><subject>Immunosuppressive Agents - administration & dosage</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Jews</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Methotrexate</subject><subject>Middle Aged</subject><subject>Pemphigus - drug therapy</subject><subject>Pemphigus - physiopathology</subject><subject>Pharmacology. Drug treatments</subject><subject>Prednisone - administration & dosage</subject><subject>Prednisone - therapeutic use</subject><subject>Reproducibility of Results</subject><subject>Retrospective Studies</subject><subject>Skin, nail, hair, dermoskeleton</subject><subject>Survival Rate</subject><issn>0190-9622</issn><issn>1097-6787</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtLAzEQgIMotVZ_QmEPInpYTTbNZnMSKT4KBQ_qOaSzkzayj5rsFvz3pg969TJzmG9eHyFjRu8ZZfnDB2WKpirPsluV3xWU5nnKTsiQUSXTXBbylAyPyDm5COGbUqomXA7IoMjjCCGGZDprbNVjA5i0Nuk8mq7GpkvaJulWmEDlGgemSqDtfdgxa6zXK7fsQ7Lpq6XxLlySM2uqgFeHPCJfL8-f07d0_v46mz7NUxBUdqmyWS4XHDOGuBCF4IoasJaXwBQAFBMjFC8NCCMXFCErJhbRcCm4KRgqzkfkZj937dufHkOnaxcAq8o02PZBSxlfZSKLoNiD4NsQPFq99q42_lczqrfy9E6e3pqJQe_kaRb7xocF_aLG8th1sBXr14e6CVGK9aYBF44Yp1wWVEXscY9hlLFx6HUAt1VcOo_Q6bJ1_xzyB7vOi_c</recordid><startdate>19960401</startdate><enddate>19960401</enddate><creator>Carson, Patrick J.</creator><creator>Hameed, Ahsan</creator><creator>Ahmed, A. Razzaque</creator><general>Mosby, Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19960401</creationdate><title>Influence of treatment on the clinical course of pemphigus vulgaris</title><author>Carson, Patrick J. ; Hameed, Ahsan ; Ahmed, A. Razzaque</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c507t-9f267b3e21eeb585390acff3dc19ccc84a593dac5a7b0ec284feea3753a81e933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Adjuvants, Pharmaceutic - administration & dosage</topic><topic>Adjuvants, Pharmaceutic - therapeutic use</topic><topic>Adult</topic><topic>Aged</topic><topic>Anti-Inflammatory Agents - administration & dosage</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Autoimmune Diseases - drug therapy</topic><topic>Autoimmune Diseases - physiopathology</topic><topic>Biological and medical sciences</topic><topic>Contraindications</topic><topic>Dermatologic Agents</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Glucocorticoids - administration & dosage</topic><topic>Glucocorticoids - therapeutic use</topic><topic>Humans</topic><topic>Immunosuppressive Agents - administration & dosage</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Jews</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Methotrexate</topic><topic>Middle Aged</topic><topic>Pemphigus - drug therapy</topic><topic>Pemphigus - physiopathology</topic><topic>Pharmacology. Drug treatments</topic><topic>Prednisone - administration & dosage</topic><topic>Prednisone - therapeutic use</topic><topic>Reproducibility of Results</topic><topic>Retrospective Studies</topic><topic>Skin, nail, hair, dermoskeleton</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Carson, Patrick J.</creatorcontrib><creatorcontrib>Hameed, Ahsan</creatorcontrib><creatorcontrib>Ahmed, A. Razzaque</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American Academy of Dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Carson, Patrick J.</au><au>Hameed, Ahsan</au><au>Ahmed, A. Razzaque</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Influence of treatment on the clinical course of pemphigus vulgaris</atitle><jtitle>Journal of the American Academy of Dermatology</jtitle><addtitle>J Am Acad Dermatol</addtitle><date>1996-04-01</date><risdate>1996</risdate><volume>34</volume><issue>4</issue><spage>645</spage><epage>652</epage><pages>645-652</pages><issn>0190-9622</issn><eissn>1097-6787</eissn><coden>JAADDB</coden><abstract>Pemphigus vulgaris (PV) is a potentially fatal autoimmune blistering disease.
Our purpose was to summarize reported results of treatment for PV and suggest a basis for future studies.
This retrospective review applies objective criteria to 77 studies published during the last half century. It inculudes only patients older than 18 years of age with idiopathic PV and excludes patients with drug-induced PV.
Systemic corticosteroids significantly (
p = 0.001) reduced the mortality rate associated with PV compared with no treatment in the presteroid era. Adjuvants used with steroids significantly (
p = 0.001) reduced the mortality rate compared with the steroid era. The mortality rate of Jewish patients is significantly (
p = 0.001) higher than for non-Jewish patients. The outcome of PV is not influenced by the site of the initial lesion.
Although the retrospective nature of this review limits its validity, we conclude prednisone with an adjuvant is the preferred treatment, and methotrexate should be avoided.</abstract><cop>New York, NY</cop><pub>Mosby, Inc</pub><pmid>8601655</pmid><doi>10.1016/S0190-9622(96)80066-1</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0190-9622 |
| ispartof | Journal of the American Academy of Dermatology, 1996-04, Vol.34 (4), p.645-652 |
| issn | 0190-9622 1097-6787 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77962152 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adjuvants, Pharmaceutic - administration & dosage Adjuvants, Pharmaceutic - therapeutic use Adult Aged Anti-Inflammatory Agents - administration & dosage Anti-Inflammatory Agents - therapeutic use Autoimmune Diseases - drug therapy Autoimmune Diseases - physiopathology Biological and medical sciences Contraindications Dermatologic Agents Disease Progression Female Glucocorticoids - administration & dosage Glucocorticoids - therapeutic use Humans Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - therapeutic use Jews Male Medical sciences Methotrexate Middle Aged Pemphigus - drug therapy Pemphigus - physiopathology Pharmacology. Drug treatments Prednisone - administration & dosage Prednisone - therapeutic use Reproducibility of Results Retrospective Studies Skin, nail, hair, dermoskeleton Survival Rate |
| title | Influence of treatment on the clinical course of pemphigus vulgaris |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T18%3A30%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Influence%20of%20treatment%20on%20the%20clinical%20course%20of%20pemphigus%20vulgaris&rft.jtitle=Journal%20of%20the%20American%20Academy%20of%20Dermatology&rft.au=Carson,%20Patrick%20J.&rft.date=1996-04-01&rft.volume=34&rft.issue=4&rft.spage=645&rft.epage=652&rft.pages=645-652&rft.issn=0190-9622&rft.eissn=1097-6787&rft.coden=JAADDB&rft_id=info:doi/10.1016/S0190-9622(96)80066-1&rft_dat=%3Cproquest_cross%3E77962152%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77962152&rft_id=info:pmid/8601655&rft_els_id=S0190962296800661&rfr_iscdi=true |